Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
20.52
-0.07 (-0.34%)
Aug 18, 2026, 1:13 PM EDT - Market open
Cullinan Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
109
Market Cap
1.32B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 18.94M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 413.80M |
| MeiraGTx Holdings | 397.50M |
| Apnimed | 120.15M |
| Immatics | 43.00M |
| Monte Rosa Therapeutics | 28.73M |
| EyePoint | 2.79M |
| Inhibrx Biosciences | 1.30M |
CGEM News
- 1 day ago - Taiho, Cullinan Therapeutics study demonstrates statistically significant PFS - TheFly
- 1 day ago - Cullinan Therapeutics price target raised to $47 from $46 at Clear Street - TheFly
- 12 days ago - Cullinan Therapeutics reports Q2 EPS (81c), consensus (85c) - TheFly
- 12 days ago - Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 12 days ago - Cullinan Therapeutics Quarterly report: Q2 2026 - Filings
- 12 days ago - Cullinan Therapeutics Earnings release: Q2 2026 - Filings
- 20 days ago - Cullinan Therapeutics price target raised to $39 from $38 at BTIG - TheFly
- 21 days ago - Cullinan Therapeutics announces End-of-Phase 1 meeting for CLN-049 with FDA - TheFly